

Sjogrens Syndrome Market, 2012 to 2023

<https://marketpublishers.com/r/S9087BA452FEN.html>

Date: December 2017

Pages: 216

Price: US\$ 4,400.00 (Single User License)

ID: S9087BA452FEN

Abstracts

Market Outline: Sjogrens Syndrome Market

Sjogrens syndrome is an immune disorder which is indicated by two common symptoms dry mouth and dry eyes. Sometimes sjogrens syndromes are associated with other immune disorders like rheumatoid arthritis and lupus. In this condition mucous membrane of mouth and eyes get affected, which results in decreased secretion of tears and saliva. Sjogrens disease can occur at any age, it is more common in women.

Market Dynamics: Sjogrens Syndrome Market

Growing incidence of sjogrens syndrome coupled with rising awareness the sjogrens syndrome are expected to drive the growth of sjogrens syndrome market. Furthermore, increase in patient pool with rheumatoid arthritis and lupus, environmental pollution, growing demand for the advanced treatments and therapies are expected to boost the growth of the sjogrens syndrome market. However, lack of awareness is a major drawback sjogrens syndrome market.

Market Scope: Sjogrens Syndrome Market

The Global Sjogrens Syndrome Market is classified on the basis of drug, type, end user, and geographical regions.

Based on drug, global sjogrens syndrome market is segmented as

- Pilocarpine
- Cyclosporine
- NSAIDS
- Hydroxychloroquine

Based on the type, global sjogrens syndrome market is segmented as

Primary Sjogrens Syndrome

Secondary Sjogrens Syndrome

Based on the End User, global sjogrens syndrome market is segmented as

Hospitals

Clinics

Pharmacies

Online pharmacies

Region Overview: Sjogrens Syndrome Market

Strong pipeline for sjogrens syndrome, high R&D investments are expected to create demand for sjogrens syndrome market. Market players are concentrated on new product innovations and launches, partnerships and collaborations, mergers and acquisitions in order to strengthen presence and product portfolio. For example, in 2014, Nicox SA launched Xailin and AdenoPlus and in June 2015, Allergan acquired Oculeve Inc to enhance its novel technologies for dry eye.

Global sjogrens syndrome market is segmented into Latin America, North America, Asia Pacific, The Middle East and Africa and Europe. North America followed by Europe holds the largest share in global sjogrens syndrome market owing to growing geriatric population, advanced healthcare system, high adoption of technological advancements. Asia Pacific region is anticipated to show rapid growth in sjogrens syndrome market owing to rise in awareness regarding the disorder, large population pool, rise in disposable income, developing healthcare infrastructure.

Competition Assessment: Sjogrens Syndrome Market

Some of the players in global sjogrens syndrome market

Allergan Inc. (Ireland)

Auven Therapeutics (U.S.)

Novartis AG (Switzerland)

Santen Pharmaceutical Co. Ltd. (Japan)

Otsuka Pharmaceutical Co., Ltd. (Japan)

Argentis Pharmaceuticals, LLC. (UK)

Nicox S.A. (France)

Key Developments

In October 2015, Allergan introduced synthetic tears REFRESH OPTIVE gel drops to relieve dry eye symptoms.

In November 2013, Nicox SA introduced advanced diagnostic panel for detection of sjogrens syndrome in early stages in U.S.

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL SJOGRENS SYNDROME MARKET INTRODUCTION

2.1. Global Sjogrens Syndrome Market – Taxonomy

2.2. Global Sjogrens Syndrome Market –Definitions

2.2.1. Drug Class

2.2.2. Distribution Channel

3. GLOBAL SJOGRENS SYNDROME MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Sjogrens Syndrome Market Dynamics – Factors Impact Analysis

3.6. Global Sjogrens Syndrome Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Sjogrens Syndrome Market – Product Innovations

4. GLOBAL SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL SJOGRENS SYNDROME MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Drug Class Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

5.1.1. Pilocarpine

5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.1.3. Market Opportunity Analysis

5.1.2. Cyclosporine

5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.2.3. Market Opportunity Analysis

5.1.3. NSAID's

5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.3. Market Opportunity Analysis

5.1.4. Hydroxychloroquine

5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.4.3. Market Opportunity Analysis

6. GLOBAL SJOGRENS SYNDROME MARKET FORECAST, BY TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Primary Sjogrens Syndrome

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.1.3. Market Opportunity Analysis

6.2. Secondary Sjogrens Syndrome

6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.3. Market Opportunity Analysis

7. MARKET OPPORTUNITY ANALYSIS GLOBAL SJOGRENS SYNDROME MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.2.3. Market Opportunity Analysis

7.3. Others

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.3.3. Market Opportunity Analysis

8. GLOBAL SJOGRENS SYNDROME MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.5.3. Market Opportunity Analysis

8.6. Global Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Disease Type, Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue

(USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1.1. Pilocarpine

9.1.1.2. Cyclosporine

9.1.1.3. NSAIDS

9.1.1.4. Hydroxychloroquine

9.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. Primary Sjogrens Syndrome

9.1.2.2. Secondary Sjogrens Syndrome

9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Hospital Pharmacies

9.1.3.2. Retail Pharmacies

9.1.3.3. Others

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Disease, Distribution Channel and Country, 2017 – 2023

9.1.6. North America Sjogrens Syndrome Market Dynamics – Trends

10. EUROPE SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Pilocarpine

10.1.1.2. Cyclosporine

10.1.1.3. NSAIDS

10.1.1.4. Hydroxychloroquine

10.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Primary Sjogrens Syndrome

10.1.2.2. Secondary Sjogrens Syndrome

10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Hospital Pharmacies

10.1.3.2. Retail Pharmacies

10.1.3.3. Others

10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

10.1.4.2. UK

10.1.4.3. France

10.1.4.4. Spain

10.1.4.5. Italy

10.1.4.6. Russia

10.1.4.7. Poland

10.1.4.8. Rest of Europe

10.1.5. Europe Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023

10.1.6. Europe Sjogrens Syndrome Market Dynamics – Trends

11. ASIA-PACIFIC SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Pilocarpine

11.1.1.2. Cyclosporine

11.1.1.3. NSAIDS

11.1.1.4. Hydroxychloroquine

11.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Primary Sjogrens Syndrome

11.1.2.2. Secondary Sjogrens Syndrome

11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Hospital Pharmacies

11.1.3.2. Retail Pharmacies

11.1.3.3. Others

11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

11.1.4.1. Japan

11.1.4.2. China

11.1.4.3. India

11.1.4.4. ASEAN

11.1.4.5. Australia & New Zealand

11.1.4.6. Rest of Asia-Pacific

11.1.5. Asia-Pacific Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023

11.1.6. Europe Sjogrens Syndrome Market Dynamics – Trends

12. LATIN AMERICA SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Pilocarpine

12.1.1.2. Cyclosporine

12.1.1.3. NSAIDS

12.1.1.4. Hydroxychloroquine

12.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Primary Sjogrens Syndrome

12.1.2.2. Secondary Sjogrens Syndrome

12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Hospital Pharmacies

12.1.3.2. Retail Pharmacies

12.1.3.3. Others

12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Brazil

12.1.4.2. Mexico

12.1.4.3. Argentina

12.1.4.4. Venezuela

12.1.4.5. Rest of Latin America

12.1.5. Latin America Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023

12.1.6. Latin America Sjogrens Syndrome Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Pilocarpine

13.1.1.2. Cyclosporine

13.1.1.3. NSAIDS

13.1.1.4. Hydroxychloroquine

13.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Primary Sjogrens Syndrome

13.1.2.2. Secondary Sjogrens Syndrome

13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Hospital Pharmacies

13.1.3.2. Retail Pharmacies

13.1.3.3. Others

13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.4.1. Gulf Cooperation Council (GCC) Countries

13.1.4.2. Israel

13.1.4.3. South Africa

13.1.4.4. Rest of MEA

13.1.5. MEA Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023

13.1.6. MEA Sjogrens Syndrome Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.3. Allergan Inc. (Ireland)

14.4. Auveon Therapeutics (U.S.)

14.5. Novartis AG (Switzerland)

14.6. Santen Pharmaceutical Co. Ltd. (Japan)

14.7. Otsuka Pharmaceutical Co., Ltd. (Japan)

14.8. Argentis Pharmaceuticals, LLC. (UK)

14.9. Nicox S.A. (France)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Sjogrens Syndrome Market, 2012 to 2023

Product link: <https://marketpublishers.com/r/S9087BA452FEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S9087BA452FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970